Back to Market返回行情

TXG 10x Genomics, Inc.

USHealthcare
$42.73-0.86%ClosedMarket Cap: $5.42B

As of 2026-07-10 16:00

Why TXG matters now

10x Genomics, Inc. (TXG) is a US stock in Healthcare. The latest InvestLog snapshot shows $42.73 with -0.86% on the session and $5.42B in market capitalization; recent performance reads 1-month +55.92% and YTD +113.09%.

The latest financial table shown here is Q1 2026, with revenue of $150.8M, net income of $-13.5M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 2.8%.

The latest indexable market news headline is "10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $22.00; recent insider activity includes SULIMAN SHEHNAAZ filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

5.48

P/S

6.91

EV/EBITDA

42.91

DCF Value

$-10.23

FCF Yield

2.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

69.6%

Operating Margin

-6.1%

Net Margin

-3.5%

ROE

-2.9%

ROA

-2.2%

ROIC

-4.2%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$150.8M$-13.5M$-0.10
Q4 2025$166.0M$-16.3M$-0.13
FY 2025$642.8M$-43.5M$-0.35
Q3 2025$149.0M$-27.5M$-0.22

Analyst Ratings

Consensus

Hold

Target (Consensus)

$22.43

Target (Median)

$22.00

Target Range

$17.00 - $30.00

Strong Buy: 1Buy: 5Hold: 10Sell: 0Strong Sell: 0
JP MorganNeutral
2026-05-12
Morgan StanleyEqual Weight
2026-05-12
B of A SecuritiesNeutral
2026-04-20
Canaccord GenuityBuy
2026-04-20
BarclaysOverweight
2026-04-14

Trading Activity

Insider Trades

SULIMAN SHEHNAAZdirector
Sell2026-06-18
SULIMAN SHEHNAAZdirector
Sell2026-06-18
Kosaraju Sridhardirector
Sell2026-06-08
MATEO ALANdirector
Sell2026-06-08
Popovits Kimberly Jdirector
Sell2026-06-08

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

2.11

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.